Q3 2026 SCHOTT Pharma AG & Co KgaA Earnings Call Transcript
Key Points
- Q3 revenue grew 8.3% at constant currencies, with broad-based demand across both segments and product lines.
- High-value solutions (HVS) revenue share reached 59% in Q3, in line with the midterm target of 60%.
- DCS segment delivered strong growth of 10.8% at constant currencies, driven by sterile cartridges, specialty vials, and ready-to-use formats.
- DDS segment showed encouraging recovery, with growth in prefillable glass syringes (GLP-1) and polymer syringes outside mRNA.
- Free cash flow improved 49% year-on-year to EUR58.9 million, reflecting better working capital and financing optimization.
- Company raised full-year guidance for revenue growth (5%-6%) and EBITDA margin (27%-28%), confirming positive momentum.
- Expansion projects in the US, Hungary, and Switzerland are on track, strengthening local-for-local capacity and HVS readiness.
- New agreement with a key glass syringe customer includes take-or-pay components, providing future revenue visibility.
- Collaboration with Nemera on pen injector compatibility with 3 mL RTU cartridges supports home-care trend and speeds time-to-market.
- New Chief Commercial Officer role enhances customer centricity and cross-departmental collaboration.
- Group EBITDA margin declined to 26.8% in Q3 from 32.3% in the prior year, impacted by lower DDS utilization and production optimization costs.
- DDS segment EBITDA margin fell to 29.4% for nine months from 35.1% in the prior year, due to lower utilization, impairment, and one-off costs.
- Nine-month net income decreased 9% year-on-year to EUR103.4 million, with EPS down to EUR0.68 from EUR0.75.
- DDS nine-month revenue was flat at constant currencies, reflecting weak H1 due to lower polymer syringe volumes for mRNA.
- Q4 DCS revenue is expected to be seasonally weaker, potentially below Q3 levels, which could temper overall growth.
- A one-off revenue contribution of approximately EUR15 million from the glass syringe agreement will create a headwind for 2027 growth comparisons.
- Production infrastructure and process optimization costs in Q3 caused temporary inefficiencies, which may recur.
- Inventory impairment on customer-specific glass syringes in H1 weighed on profitability.
- DCS margin declined sequentially from Q2 to Q3 due to product mix, with a weaker HVS share in Q3.
- Management did not provide specific guidance for 2027, leaving uncertainty about growth sustainability beyond the current year.
Gentlemen, and welcome to SCHOTT Pharma's earning call for the third quarter and the first nine months of 2026. The conference will be recorded. (Operator Instructions)
Let me now turn the floor over to your host, Tobias Erfurth.
Thank you very much, Parisa. And good morning to everyone on the call.
Welcome to our nine-month, third quarter conference call for the financial year 2026. My name is Tobias Erfurth, Head of Investor Relations and Communications, and I will be guiding you through today's session.
With me are our CEO, Christian Mias, and our CFO, Reinhard Mayer. Christian will begin with a business update, followed by Reinhard, who will walk you through our financial performance in more detail. After that, we will open the call for your questions.
Before we kick off, please take a moment to review our disclaimer on slide number 2. It covers our standard Safe Harbor language for forward-looking statements. As a reminder,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
